Plasma homocysteine and risk of mild cognitive impairment

Christiane Reitz, Ming Xin Tang, Joshua Miller, Ralph Green, José A. Luchsinger

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background and Objective: There are conflicting data relating homocysteine levels to the risk of Alzheimer's disease (AD). We sought to explore whether fasting plasma homocysteine is associated with the risk of mild cognitive impairment (MCI), an intermediate stage to dementia. Methods: Fasting levels of plasma homocysteine were obtained from 678 elderly subjects chosen at random from a cohort of Medicare recipients. There were longitudinal data in 516 subjects without MCI or dementia at baseline who were followed for 2,705 person-years. The relation of plasma homocysteine with prevalent and incident all-cause MCI, amnestic MCI and non-amnestic MCI was assessed using logistic and Cox proportional hazards regression analyses. Results: There were 162 cases of prevalent MCI and 132 cases of incident MCI in 5.2 years of follow-up. There was no association between plasma homocysteine and prevalence of MCI or amnestic or non-amnestic MCI in the cross-sectional analyses. There was no association between higher homocysteine levels and a lower risk of all-cause MCI. Consistent with the cross-sectional analyses, there was no specific association with the amnestic or non-amnestic subtype of MCI in crude or adjusted models. Conclusion: Plasma homocysteine levels measured at baseline were not related to MCI or its subtypes in an elderly multiethnic cohort.

Original languageEnglish (US)
Pages (from-to)11-17
Number of pages7
JournalDementia and Geriatric Cognitive Disorders
Volume27
Issue number1
DOIs
StatePublished - Feb 2009

Fingerprint

Homocysteine
Dementia
Cognitive Dysfunction
Fasting
Cross-Sectional Studies
Medicare
Alzheimer Disease
Regression Analysis

Keywords

  • Dementia
  • Homocysteine
  • Mild cognitive impairment

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Geriatrics and Gerontology
  • Cognitive Neuroscience

Cite this

Plasma homocysteine and risk of mild cognitive impairment. / Reitz, Christiane; Tang, Ming Xin; Miller, Joshua; Green, Ralph; Luchsinger, José A.

In: Dementia and Geriatric Cognitive Disorders, Vol. 27, No. 1, 02.2009, p. 11-17.

Research output: Contribution to journalArticle

Reitz, Christiane ; Tang, Ming Xin ; Miller, Joshua ; Green, Ralph ; Luchsinger, José A. / Plasma homocysteine and risk of mild cognitive impairment. In: Dementia and Geriatric Cognitive Disorders. 2009 ; Vol. 27, No. 1. pp. 11-17.
@article{4e9cfc26062b4f39a088af7861a6903c,
title = "Plasma homocysteine and risk of mild cognitive impairment",
abstract = "Background and Objective: There are conflicting data relating homocysteine levels to the risk of Alzheimer's disease (AD). We sought to explore whether fasting plasma homocysteine is associated with the risk of mild cognitive impairment (MCI), an intermediate stage to dementia. Methods: Fasting levels of plasma homocysteine were obtained from 678 elderly subjects chosen at random from a cohort of Medicare recipients. There were longitudinal data in 516 subjects without MCI or dementia at baseline who were followed for 2,705 person-years. The relation of plasma homocysteine with prevalent and incident all-cause MCI, amnestic MCI and non-amnestic MCI was assessed using logistic and Cox proportional hazards regression analyses. Results: There were 162 cases of prevalent MCI and 132 cases of incident MCI in 5.2 years of follow-up. There was no association between plasma homocysteine and prevalence of MCI or amnestic or non-amnestic MCI in the cross-sectional analyses. There was no association between higher homocysteine levels and a lower risk of all-cause MCI. Consistent with the cross-sectional analyses, there was no specific association with the amnestic or non-amnestic subtype of MCI in crude or adjusted models. Conclusion: Plasma homocysteine levels measured at baseline were not related to MCI or its subtypes in an elderly multiethnic cohort.",
keywords = "Dementia, Homocysteine, Mild cognitive impairment",
author = "Christiane Reitz and Tang, {Ming Xin} and Joshua Miller and Ralph Green and Luchsinger, {Jos{\'e} A.}",
year = "2009",
month = "2",
doi = "10.1159/000182421",
language = "English (US)",
volume = "27",
pages = "11--17",
journal = "Dementia and Geriatric Cognitive Disorders",
issn = "1420-8008",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - Plasma homocysteine and risk of mild cognitive impairment

AU - Reitz, Christiane

AU - Tang, Ming Xin

AU - Miller, Joshua

AU - Green, Ralph

AU - Luchsinger, José A.

PY - 2009/2

Y1 - 2009/2

N2 - Background and Objective: There are conflicting data relating homocysteine levels to the risk of Alzheimer's disease (AD). We sought to explore whether fasting plasma homocysteine is associated with the risk of mild cognitive impairment (MCI), an intermediate stage to dementia. Methods: Fasting levels of plasma homocysteine were obtained from 678 elderly subjects chosen at random from a cohort of Medicare recipients. There were longitudinal data in 516 subjects without MCI or dementia at baseline who were followed for 2,705 person-years. The relation of plasma homocysteine with prevalent and incident all-cause MCI, amnestic MCI and non-amnestic MCI was assessed using logistic and Cox proportional hazards regression analyses. Results: There were 162 cases of prevalent MCI and 132 cases of incident MCI in 5.2 years of follow-up. There was no association between plasma homocysteine and prevalence of MCI or amnestic or non-amnestic MCI in the cross-sectional analyses. There was no association between higher homocysteine levels and a lower risk of all-cause MCI. Consistent with the cross-sectional analyses, there was no specific association with the amnestic or non-amnestic subtype of MCI in crude or adjusted models. Conclusion: Plasma homocysteine levels measured at baseline were not related to MCI or its subtypes in an elderly multiethnic cohort.

AB - Background and Objective: There are conflicting data relating homocysteine levels to the risk of Alzheimer's disease (AD). We sought to explore whether fasting plasma homocysteine is associated with the risk of mild cognitive impairment (MCI), an intermediate stage to dementia. Methods: Fasting levels of plasma homocysteine were obtained from 678 elderly subjects chosen at random from a cohort of Medicare recipients. There were longitudinal data in 516 subjects without MCI or dementia at baseline who were followed for 2,705 person-years. The relation of plasma homocysteine with prevalent and incident all-cause MCI, amnestic MCI and non-amnestic MCI was assessed using logistic and Cox proportional hazards regression analyses. Results: There were 162 cases of prevalent MCI and 132 cases of incident MCI in 5.2 years of follow-up. There was no association between plasma homocysteine and prevalence of MCI or amnestic or non-amnestic MCI in the cross-sectional analyses. There was no association between higher homocysteine levels and a lower risk of all-cause MCI. Consistent with the cross-sectional analyses, there was no specific association with the amnestic or non-amnestic subtype of MCI in crude or adjusted models. Conclusion: Plasma homocysteine levels measured at baseline were not related to MCI or its subtypes in an elderly multiethnic cohort.

KW - Dementia

KW - Homocysteine

KW - Mild cognitive impairment

UR - http://www.scopus.com/inward/record.url?scp=57649083123&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57649083123&partnerID=8YFLogxK

U2 - 10.1159/000182421

DO - 10.1159/000182421

M3 - Article

C2 - 19088473

AN - SCOPUS:57649083123

VL - 27

SP - 11

EP - 17

JO - Dementia and Geriatric Cognitive Disorders

JF - Dementia and Geriatric Cognitive Disorders

SN - 1420-8008

IS - 1

ER -